Literature DB >> 33727376

Medication use during COVID-19: Review of recent evidence.

T S Brandon Ng1, Kori Leblanc2, Darwin F Yeung3, Teresa S M Tsang4.   

Abstract

OBJECTIVE: To keep health care providers, in response to the ongoing coronavirus disease 2019 (COVID-19) pandemic, informed about the medications that have been proposed to treat the disease and the evidence supporting their use. QUALITY OF EVIDENCE: A narrative review of medications most widely used to treat COVID-19 was conducted, outlining the best available evidence for each pharmacologic treatment to date. Searches were performed in PubMed, EMBASE, and MEDLINE using key words COVID-19 and treatment, as well as related terms. Relevant research studies conducted in human populations and cases specific to patients with COVID-19 were included, as were relevant hand-searched papers and reviews. Only articles in English and Chinese were included. MAIN MESSAGE: While current management of patients with COVID-19 largely involves supportive care, without a widely available vaccine, practitioners have also resorted to repurposing medications used for other indications. This has caused considerable controversy, as many of these treatments have limited clinical evidence supporting their use and therefore pose implications for patient safety, drug access, and public health. For instance, medications such as hydroxychloroquine and chloroquine, lopinavir-ritonavir, nonsteroidal anti-inflammatory drugs, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers gained widespread media attention owing to hype, misinformation, or misinterpretation of research evidence.
CONCLUSION: Given the severity of the pandemic and the potential broad effects of implementing safe and effective treatment, this article provides a narrative review of the current evidence behind the most widely used medications to treat COVID-19 in order to enable health care practitioners to make informed decisions in the care of patients with this life-threatening disease. Copyright
© 2021 the College of Family Physicians of Canada.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33727376      PMCID: PMC7963004          DOI: 10.46747/cfp.6703171

Source DB:  PubMed          Journal:  Can Fam Physician        ISSN: 0008-350X            Impact factor:   3.275


  84 in total

1.  [Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia].

Authors: 
Journal:  Zhonghua Jie He He Hu Xi Za Zhi       Date:  2020-03-12

2.  Clinical efficacy of lopinavir/ritonavir in the treatment of Coronavirus disease 2019.

Authors:  X-T Ye; Y-L Luo; S-C Xia; Q-F Sun; J-G Ding; Y Zhou; W Chen; X-F Wang; W-W Zhang; W-J Du; Z-W Ruan; L Hong
Journal:  Eur Rev Med Pharmacol Sci       Date:  2020-03       Impact factor: 3.507

3.  [Clinical characteristics and outcomes of 112 cardiovascular disease patients infected by 2019-nCoV].

Authors:  Y D Peng; K Meng; H Q Guan; L Leng; R R Zhu; B Y Wang; M A He; L X Cheng; K Huang; Q T Zeng
Journal:  Zhonghua Xin Xue Guan Bing Za Zhi       Date:  2020-06-24

4.  Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients With Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19: The CoDEX Randomized Clinical Trial.

Authors:  Bruno M Tomazini; Israel S Maia; Alexandre B Cavalcanti; Otavio Berwanger; Regis G Rosa; Viviane C Veiga; Alvaro Avezum; Renato D Lopes; Flavia R Bueno; Maria Vitoria A O Silva; Franca P Baldassare; Eduardo L V Costa; Ricardo A B Moura; Michele O Honorato; Andre N Costa; Lucas P Damiani; Thiago Lisboa; Letícia Kawano-Dourado; Fernando G Zampieri; Guilherme B Olivato; Cassia Righy; Cristina P Amendola; Roberta M L Roepke; Daniela H M Freitas; Daniel N Forte; Flávio G R Freitas; Caio C F Fernandes; Livia M G Melro; Gedealvares F S Junior; Douglas Costa Morais; Stevin Zung; Flávia R Machado; Luciano C P Azevedo
Journal:  JAMA       Date:  2020-10-06       Impact factor: 56.272

5.  Cardiac Involvement in a Patient With Coronavirus Disease 2019 (COVID-19).

Authors:  Riccardo M Inciardi; Laura Lupi; Gregorio Zaccone; Leonardo Italia; Michela Raffo; Daniela Tomasoni; Dario S Cani; Manuel Cerini; Davide Farina; Emanuele Gavazzi; Roberto Maroldi; Marianna Adamo; Enrico Ammirati; Gianfranco Sinagra; Carlo M Lombardi; Marco Metra
Journal:  JAMA Cardiol       Date:  2020-07-01       Impact factor: 14.676

6.  2019 Novel Coronavirus (COVID-19) Pneumonia: Serial Computed Tomography Findings.

Authors:  Jiangping Wei; Huaxiang Xu; Jingliang Xiong; Qinglin Shen; Bing Fan; Chenglong Ye; Wentao Dong; Fangfang Hu
Journal:  Korean J Radiol       Date:  2020-02-26       Impact factor: 3.500

7.  Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.

Authors:  Manli Wang; Ruiyuan Cao; Leike Zhang; Xinglou Yang; Jia Liu; Mingyue Xu; Zhengli Shi; Zhihong Hu; Wu Zhong; Gengfu Xiao
Journal:  Cell Res       Date:  2020-02-04       Impact factor: 25.617

8.  Tocilizumab, an anti-IL-6 receptor antibody, to treat COVID-19-related respiratory failure: a case report.

Authors:  J-M Michot; L Albiges; N Chaput; V Saada; F Pommeret; F Griscelli; C Balleyguier; B Besse; A Marabelle; F Netzer; M Merad; C Robert; F Barlesi; B Gachot; A Stoclin
Journal:  Ann Oncol       Date:  2020-04-02       Impact factor: 32.976

9.  Evolution of Computed Tomography Manifestations in Five Patients Who Recovered from Coronavirus Disease 2019 (COVID-19) Pneumonia.

Authors:  Qiulian Sun; Xinjian Xu; Jicheng Xie; Jingjing Li; Xiangzhong Huang
Journal:  Korean J Radiol       Date:  2020-03-13       Impact factor: 3.500

10.  Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality.

Authors:  Chi Zhang; Zhao Wu; Jia-Wen Li; Hong Zhao; Gui-Qiang Wang
Journal:  Int J Antimicrob Agents       Date:  2020-03-29       Impact factor: 5.283

View more
  2 in total

1.  Physician questions and concerns related to COVID-19: a content analysis of advice calls to a medico-legal helpline.

Authors:  Jacqueline H Fortier; Allan McDougall; Cathy Zhang; Caroline Ehrat; Giuseppe Ficara; Ann Cranney; Gary Garber
Journal:  CMAJ Open       Date:  2022-08-02

Review 2.  Les misérables: a Parallel Between Antimicrobial Resistance and COVID-19 in Underdeveloped and Developing Countries.

Authors:  Genesy Pérez Jorge; Isabella Carolina Rodrigues Dos Santos Goes; Marco Tulio Pardini Gontijo
Journal:  Curr Infect Dis Rep       Date:  2022-10-04       Impact factor: 3.663

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.